NDC product
Zepbound
NDC 0002-2002 · Eli Lilly and Company
Key facts
| Product NDC | 0002-2002 |
|---|---|
| Proprietary name | Zepbound |
| Nonproprietary name | tirzepatide |
| Substances | TIRZEPATIDE |
| Dosage form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Labeler | Eli Lilly and Company |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA217806 |
| Pharmacologic classes | G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] |
| Marketing start | Mar 28, 2024 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: